Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma, M. M., Sanchez, L., Ojeda, D. S., Oviedo Rouco, S., Rossi, A. H., Varese, A., Mazzitelli, I., Pascuale, C. A., Miglietta, E. A., Rodriguez, P. E., Pallares, H. M., Costa Navarro, G. S., Caramelo, J. J., Rothlauf, P. W., Liu, Z., Bloyet, L. M., Cornejo Pontelli, M., Rasetto, N. B., Wenker, S. D., Ramis, L. Y., Bialer, M. G., de Leone, M. J., Hernando, C. E., Bianchimano, L., Rios, A. S., Treffinger Cienfuegos, M. S., Rodriguez Garcia, D. R., Longueira, Y., Laufer, N., Alvarez, D., Ceballos, A., Ochoa, V., Monzani, C., Turk, G., Salvatori, M., Carradori, J., Prost, K., Rima, A., Varela, C., Ercole, R., Toro, R. I., Gutierrez, S., Zubieta, M., Acuna, D., Nabaes Jodar, M. S., Torres, C., Mojsiejczuk, L., Viegas, M., Velazquez, P., Testa, C., Kreplak, N., Yanovsky, M., Whelan, S., Geffner, J., Pifano, M. and Gamarnik, A. V.
Fundacion Instituto Leloir-CONICET, Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomedicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina.
Instituto de Investigaciones Biotecnologicas, UNSAM-CONICET, Buenos Aires, Argentina.
Laboratorio Lemos S.R.L., Buenos Aires, Argentina.
Hospital Interzonal General de Agudos Dr Pedro Fiorito, Buenos Aires, Argentina.
Hospital Interzonal General de Agudos Evita, Buenos Aires, Argentina.
Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Buenos Aires, Argentina.
Hospital Interzonal Especializado de Agudos y Cronicos San Juan de Dios, Buenos Aires, Argentina.
Hospital Interzonal General de Agudos San Roque, Buenos Aires, Argentina.
Hospital Interzonal General de Agudos San Martin, Buenos Aires, Argentina.
Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Buenos Aires, Argentina.
Hospital General de Ninos Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriologia y Virologia Molecular, Fac de Farmacia y Bioquimica, UBA, Buenos Aires, Argentina.
Ministerio de Salud de Provincia de Buenos Aires, Buenos Aires, Argentina.
Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples (N = 536) collected from 118 volunteers obtained between January and October 2021 were used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least 6 months and show a reduction of VOC escape to neutralizing antibodies over time after vaccination. IMPORTANCE Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation. Sputnik V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and other developing countries, but limited information is available about its elicited immune responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination. In addition, we observed an increased cross-neutralization activity over time for the Beta and Gamma variants. This study provides valuable information about the immune response generated by a vaccine platform used in many parts of the world.
mBio : e0344221 (2022)